Gail F. Levine

Gail Levine co-leads the firm’s global Antitrust & Competition practice, which was recently recognized once again as among Global Competition Review’s “Global Elite.” Gail is a trusted advisor to clients with business-critical mergers or acquisitions facing antitrust issues. Her clients include Fortune 500 companies and PE firms, and she handles their merger control matters, 
represents them in investigations, and counsels them on antirust risk. She is a trusted advisor to small and growing tech start-ups, counseling them in a wide variety of issues as they scale. She also represents high-tech companies in data privacy and security FTC investigations.

She joined Mayer Brown from the Federal Trade Commission’s Bureau of Competition, where she served as a deputy director under Chairman Joseph Simons and Acting Chairwoman Rebecca Slaughter.

• Handling all aspects of antitrust M&A reviews, including analysis that starts before the deal is even signed: evaluating antitrust risks of potential deals, advising senior leadership on antitrust risks and how to mitigate them, counseling on deal sequencing, and more.
• Counseling clients on antitrust questions critical to their business, including questions about how to minimize the risk that strong business moves today will draw antitrust litigation in the future, how to train workforces to avoid antitrust violations, and more.
• Defending clients in antitrust and other FTC investigations, including responding to civil investigative demands, building defenses, and advising on negotiating settlements.
• Advising investors on antitrust issues that can move the market, such as analyzing likelihood of whether the antitrust authorities will challenge a particular deal, whether the courts will agree with the agencies’ positions, and what the market impact of an interim order will be.

While at the FTC:

• Supervised FTC challenge to a next-generation gene-sequencing firm’s plan to acquire an alleged nascent competitor (Illumina/PacBio).
• Oversaw FTC’s action against a pharmaceutical firm and its corporate leadership for allegedly using anticompetitive tactics to shield its drug from price competition (FTC v. Vyera).
• Supervised the FTC’s actions against drug companies that allegedly used an anticompetitive product-hopping scheme to thwart competition with their lucrative opioid replacement therapy drug. The companies paid $60 million to settle the charges, which has been refunded to consumers.
• Helped establish, and supervised, the FTC’s Technology Enforcement Division, which investigates anticompetitive conduct in digital technology markets.
• Oversaw the FTC’s successful challenge to Peabody/Arch Coal, a proposed joint venture in the coal industry.

• Global Competition Review Recognizes Mayer Brown Among Global Elite
• FTC's Janet Steiger Award (2019) for outstanding contributions to Chairman's 21st Century Hearings Team
• FTC's Janet Steiger Award (2004) for exceptional effort on FTC health care hearings and report
• FTC's Outstanding Team Effort Award (2003) for outstanding work on FTC's IP hearings and report

• Harvard Law School, JD, magna cum laude
  

  Harvard Law Review

• University of Texas, BA, summa cum laude
  

  Phi Beta Kappa; Plan II Honors Program; Outstanding Student Finalist; Dean’s Distinguished Graduate

• District of Columbia
• Texas

• American Bar Association, Section of Antitrust Law: Vice Chair, Women.Connected (2020-present); Member, Council (2013-2016); Member, Long Range Planning Committee (2020-present; 2013-2014); Member, Nominating Committee (2011); Co-Chair, Communications & Digital Technologies Industry Committee (2009-2011); Vice Chair, Computer & Internet Committee (2001-2009)
• ABA Presidential Transition Task Force: Advisor on competition, innovation, and consumer protection policy (2012-2013)
• ABA Presidential Task Force on Pleading Standards (2010-2011)